HB 1225 (2024): relative to prescription drug affordability board conflicts of interest.

Cite this page

Granite Record indexes the General Court’s record; it is not that record. Where a citation allows only one source, cite the General Court — every page here links to what it is drawn from. The date below is the day the page was read.

MLA: “HB 1225 (2024): relative to prescription drug affordability board conflicts of interest.” Granite Record, https://graniterecord.org/bill/2024/hb1225. Accessed 24 Oct. 2026.
APA: Granite Record. (n.d.). HB 1225 (2024): relative to prescription drug affordability board conflicts of interest. Retrieved 24 Oct. 2026, from https://graniterecord.org/bill/2024/hb1225
Chicago: Granite Record. “HB 1225 (2024): relative to prescription drug affordability board conflicts of interest.” Accessed 24 Oct. 2026. https://graniterecord.org/bill/2024/hb1225.
BibTeX: @misc{bill-2024-hb1225, title = {HB 1225 (2024): relative to prescription drug affordability board conflicts of interest.}, howpublished = {Granite Record}, url = {https://graniterecord.org/bill/2024/hb1225}, note = {Accessed 24 Oct. 2026} }

HB 1225 (2024)

relative to prescription drug affordability board conflicts of interest.

Status: Referred for interim study
Term: 2023-2024
House committee: Commerce and Consumer Affairs
Subject: Public and Mental Health

The Story

It was introduced on January 3, 2024 and referred to the House Commerce and Consumer Affairs committee. The committee held a public hearing on January 18, 2024, with one person signed in online in support. The committee held work sessions on February 14, 2024 and February 20, 2024. The committee met in executive session on March 13, 2024 to vote on its recommendation. The committee voted unanimously, 18–0, to recommend that the House study it after the session ends, and the report was placed on the consent calendar. On March 28, 2024 the House voted to study it after the session ends on a voice vote. The committee held a work session on September 12, 2024. The committee met in executive session on October 17, 2024 to vote on its recommendation. The committee reported back on its interim study of the bill: “Not Recommended for Future Legislation”, by a vote of 16 to 0.

Hearings and Sessions

January 18, 2024, 10:15 AM: public hearing, House Commerce and Consumer Affairs, LOB 302-304
February 14, 2024, 10:00 AM: subcommittee work session, House Commerce and Consumer Affairs, LOB 302-304
February 20, 2024, 10:00 AM: subcommittee work session, House Commerce and Consumer Affairs, LOB 305
March 13, 2024, 10:00 AM: executive session, House Commerce and Consumer Affairs, LOB 302-304
September 12, 2024, 10:00 AM: subcommittee work session, House Commerce and Consumer Affairs, LOB 302-304
October 17, 2024, 10:00 AM: executive session, House Commerce and Consumer Affairs, LOB 302-304

Votes

March 28, 2024, House: Refer for Interim Study — voice vote, passed

The Docket

January 3, 2024: Introduced 01/03/2024 and referred to Commerce and Consumer Affairs
January 18, 2024: Public Hearing: 01/18/2024 10:15 am LOB 302-304
February 14, 2024: Subcommittee Work Session: 02/14/2024 10:00 am LOB 302-304
February 20, 2024: Subcommittee Work Session: 02/20/2024 10:00 am LOB 305
March 13, 2024: Executive Session: 03/13/2024 10:00 am LOB 302-304
March 13, 2024: Committee Report: Refer for Interim Study 03/13/2024 (Vote 18-0; CC)
March 28, 2024: Refer for Interim Study: MA VV 03/28/2024
September 12, 2024: Full Committee Subcommittee Work Session: 09/12/2024 10:00 am LOB 302-304
October 17, 2024: Executive Session: 10/17/2024 10:00 am LOB 302-304
October 31, 2024: Interim Study Report: Not Recommended for Future Legislation (Vote 16-0)

Laws It Would Change

RSA 126-BB:3